Japan approves remdesivir for COVID-19 patients

Veklury (remdesivir) has been approved in Japan as a treatment for COVID-19 under an exceptional approval pathway, Gilead has announced.

The exceptional approval was granted in the wake of the COVID-19 pandemic and references the Emergency Use Authorisation of remdesivir in the United States.

The approval is based on clinical data from the US National Institute of Allergy and Infectious Diseases’ global Phase 3 trial, Gilead’s Phase 3 SIMPLE trial in patients with severe manifestations of COVID-19, and available data from Gilead’s compassionate use program, including patients in Japan.

“The Japanese approval of remdesivir is in recognition of the urgent need to treat critically ill patients in Japan. It is a reflection of the exceptional circumstances of this pandemic,” said Merdad Parsey, Chief Medical Officer at Gilead Sciences.

Remdesivir is not yet licensed or approved outside of Japan and ongoing clinical trials continue to evaluate its safety and efficacy. Gilead continues to work with global regulatory authorities to ensure appropriate access to remdesivir.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce...

Tecentriq combination approved for advanced melanoma

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety...

European approval for Novartis’ Cosentyx in paediatric psoriasis

Novartis has gained European approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The...

Hetero cleared to launch first remdesivir generic in India

Hetero, one of India’s leading generic pharmaceutical companies, has received the manufacturing and marketing approval for remdesivir from the Drug Controller General of India...

Collaboration to develop stem cell therapies for COVID-19 and future pandemic diseases

Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, has expanded its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell...

Related news

In brief: Sanofi & GSK in talks to supply 300m doses of COVID vaccine to EU

Sanofi and GlaxoSmithKline (GSK) are in “advanced discussions” with the European Commission (EC) for the supply of up to 300 million doses of a...

Intravacc & Celonic to develop, produce novel COVID-19 vaccine

Intravacc, a Dutch viral and bacterial vaccine specialist, and Swiss CDMO, Celonic Group, have signed a research agreement to further design, develop and produce...

Tecentriq combination approved for advanced melanoma

The FDA has approved Roche’s Tecentriq (atezolizumab) plus Cotellic (cobimetinib) and Zelboraf (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients. The safety...

European approval for Novartis’ Cosentyx in paediatric psoriasis

Novartis has gained European approval for Cosentyx (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. The...